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Homology between p63 and p53 has suggested that these proteins
might function similarly. However, the majority of data from
human tumors have not supported a similar role for p63 in tumor
suppression. To investigate this issue, we studied spontaneous
tumorigenesis in p63 mice in both WT and p53-compromised
backgrounds. We found that p63 mice were not tumor prone
and mice heterozygous for both p63 and p53 had fewer tumors
than p53 mice. The rare tumors that developed in mice with
compromised p63 were also distinct from those of p53 mice.
Furthermore, p63 mice were not prone to chemically induced
tumorigenesis, and p63 expression was maintained in carcinomas.
These findings demonstrate that, in agreement with data from
human tumors, p63 plays a markedly different biological role in
cancer than p53.
mouse model  p53  tumor suppressor  cancer
The p63 protein is a member of the p53 family that includes p53,p63, and p73, which share extensive homology within the core
DNA binding domain (DBD) (reviewed in ref. 1). A well estab-
lished feature of p53 is that it is frequently lost or inactivated in a
variety of human cancers (2). Although some evidence suggests that
p63 may perform biological roles analogous to those of p53 (3, 4),
p63 is rarelymutated, and p63 expression is often retained in human
tumors (reviewed in ref. 5). Althoughmutations in human p63 have
been identified, these mutations cause severe birth anomalies, and
tumor susceptibility is not a typical feature of these syndromes (1).
In contrast to p53’s ubiquitous pattern of expression, p63 is most
readily detectable in proliferating cells of stratified squamous
epithelia such as the skin, the precursor cell type for the majority
of human cancers. Interactions between p63 and p53 and subse-
quent degradation of p63 can occur when p53 contains tumor-
derived missense mutations, suggesting that p63 could affect the
tumor-suppressive capabilities of p53 (6). Thus, p63’s role in
modulating tumor-suppressive mechanisms in vivo has not been
fully evaluated.
To investigate whether p63 functions as a tumor suppressor in the
intact organism, we evaluated spontaneous and chemically induced
tumorigenesis in mice with decreased levels of p63. In addition,
spontaneous tumors were monitored in mice that had reduced
levels of p63 in combination with compromised levels of p53 to
assess whether combined p63 and p53 deficiency affects tumori-
genesis in vivo.
Results
p63Mice Are Not Predisposed to Spontaneous Tumors. p53
and p53mice are highly tumor-pronewith themajority ofmice
developing spontaneous tumors by 10 months and 2 years, respec-
tively (7, 8). To determine the impact of compromised p63 on
tumorigenesis, we performed a spontaneous tumor study of 153
p63 mice and sibling controls for 2 years. Mice lacking p63
die shortly after birth (9, 10), and therefore the effect of germ-line
deficiency of p63 in cancer could not be evaluated in p63mice.
We had previously disrupted the endogenous p63 locus and gen-
erated two distinct p63 null alleles, p63Brdm1 and p63Brdm2 (9) (Fig.
1 A and B). While characterizing the endogenous p63 allele, we
discovered that the previously reported genomic structure (4) was
incorrect; the relative position of the exons (and hence the splicing
pattern) was not accurately depicted (Fig. 1A). Because endoge-
nous p63 transcripts were not detected in mice homozygous for
either p63Brdm1 or p63Brdm2, both of these alleles are presumably
functionally null and therefore deficient for all functional p63
isoforms. To avoid the possibility of founder effects, the p63
cohort was derived from three independently targeted embryonic
stem cell clones. Mice were monitored for spontaneous tumors
twice weekly, and those that had palpable lesions or weremoribund
were killed and subjected to macroscopic analysis. Detailed histo-
pathology was performed on 104 p63mice and 18 WT sibling
controls. In addition, an archival tumor study of 56WTcontrolmice
conducted in the same facility was included for reference. Details
on the genetic background for these cohorts are shown in Table 2,
which is published as supporting information on the PNASweb site.
By the 115-week time point, only a small percentage (13%) of
p63 mice developed tumors, significantly fewer than WT
controls (38%) (P 0.001) (Fig. 2A andB). At the end of the study,
a total of 36 neoplasms were characterized from the WT cohort
(n 74). In contrast, only 13 neoplasms developed in 104 p63
mice. The tumor class, age of onset, body site affected, and the
particular null p63 allele in the tumor-bearing p63 mice are
shown in Table 3, which is published as supporting information on
the PNAS web site. Neither p63Brdm1 nor p63Brdm2 mice
developed the early tumors typical of p53 mice, although the
majority of the p63 cohort consisted of mice heterozygous for
the p63Brdm2 allele. Thus, mice with haploid levels of p63 are distinct
from p53 mice; they are not predisposed to spontaneous
tumors.
p63 Mice Develop Nonmalignant Pathology. During the course
of this tumor study, we found that p63 mice often developed
nonmalignant pathology consistent with features of accelerated
aging (11). Although this phenotype often suggested malignancy,
the majority of p63 animals were free of tumors upon autopsy
and histological analyses. Epithelial hyperplasia was frequently
observed; however, these lesions did not progress to tumors. To
account for nontumor-related deaths, Kaplan–Meier analysis was
performedon the entire cohort, with censoring of animals that were
tumor free (Fig. 2C). This analysis further shows that the rare
tumors that develop in p63 mice do not have a significantly
earlier onset than tumors in WT mice, and that these mice do not
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exhibit the high tumor incidence characteristic of p53mice (7,
8). In addition to epithelial hyperplasia, reactive inflammatory
disease affecting the spleen, salivary glands, lymph nodes, and liver
was observed in 77% (n 82) of the p63mice. This pathology
involved chronic inflammation and reactive hyperplasia of lym-
phoid tissues, including myeloid hyperplasia, plasma cell prolifer-
ation, and varying degrees of lymphoid atypia. Because of their
unique pathology, these lesions could easily be misdiagnosed as
lymphomas.
p63 Heterozygosity Decreases Tumor Incidence in p53 Mice. To
determinewhether p63heterozygosity could affect tumorigenesis in
a p53-compromised background, cohorts of p63 mice in a
p53 (n  47) or p53 (n  28) background and p53-
compromised sibling controls (n  14) were generated (Fig. 1C)
and monitored for spontaneous tumors. Archival tumor data from
p53 (n  217) and p53 (n  72) mice conducted in the
same facility were included for reference. For genetic background
seeTable 2.A comparison of tumor incidence of p63micewith
both the p53 and p63;p53 cohorts was statistically
significant (P  0.001 and 0.01, respectively) (Fig. 2 A and B). At
72 weeks,50% of the p53 cohort had developed tumors, but
2%of p63mice and only 28%of p63;p53mice had
developed tumors at the same time point. Using Kaplan–Meier
analysis to factor in nontumor-related deaths, the difference be-
tween p63 or p63;p53 and the p53 cohorts was
significantly different (P  0.0001 and 0.0009 respectively). These
data indicate that combined p63 and p53 deficiency does not
exacerbate tumor incidence; instead it appears that p63 heterozy-
gosity reduces tumorigenesis in mice with compromised levels
of p53.
The Tumor Spectrum of p63 Mice Is Distinct from That of p53
Compromised Mice. Themost common tumor types in p53 and
p53 mice are sarcoma and lymphoma, respectively (7, 8). To
investigate whether p63 deficiency would generate similar types of
tumors, we analyzed the tumor spectrum in mice of different
genotypes (Table 1). WT mice developed lymphomas most fre-
quently; from 36 of the characterized neoplasms, 67% were lym-
phomas (n  24), 14% were sarcomas (n  5), and 19% were
carcinomas (n 7). In the 13 neoplasms that developed in p63
mice, 39% were lymphomas (n  5), 15% were sarcomas (n  2),
and 39% were carcinomas (n 5). When taken as a percentage of
the total cohort, all tumor types occurred less frequently in p63
mice relative to WT controls (Table 1). Consistent with previous
reports, we found sarcomas and lymphomas in the majority of
p53 (59%) and p53 (64%) mice, respectively. However,
mice with combined p63 and p53 deficiency developed a distinct
Fig. 1. p63 mouse models. (A) Schematic diagram of p63 with exons (rectangles) encoding the transactivating domain (blue), DBD (red), oligomerization
domain (green), and sterile  motif (light gray) (GenBank accession no. AF533892). In contrast to previous reports the last exon of the  isoform, exon 10
(previously referred to as exon 15) is located between exons 10 and 11, which is also the case for human p63 (data not shown). (B) Structure of the previously
generated p63Brdm1 and p63Brdm2 null alleles is shown (9). (C) Genotyping by Southern blot analysis identifies endogenous (E) and targeted (T) alleles for both
p63 and p53. P denotes the p53 pseudogene.
Fig. 2. Spontaneous tumor incidence is reduced by p63 heterozygosity. (A)
The percentage of tumor-free WT, p63, p53, p63;p53,
p53, and p63;p53 mice is shown. (B) Tumor incidence at 115
weeks is dramatically reduced in mice haploid for p63. The numbers of mice
subjected to detailed histopathology were: p63, 74; p63, 104;
p53, 225; p63;p53, 47; p53, 78; and p63;p53, 28.
(C) Tumor onset depicted by using the Kaplan–Meier format. Note that even
though overall tumor onset of p63 and p63 cohorts appears similar
when nontumor deaths are excluded, p63 mice develop significantly
fewer tumors than WT mice. In addition, tumor onset is significantly delayed
in mice heterozygous for both p63 and p53 relative to p53 mice.
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spectrum of tumors. In the p63;p53 cohort there were
19% lymphomas (n  5), 63% sarcomas (n  17), and 19%
carcinomas (n 5). In contrast to the predominance of lymphomas
characteristic of p53 mice, sarcomas were most frequent in
p63;p53 mice; of 32 neoplasms, 44% were lymphomas
(n  14) and 56% were sarcomas (n  18). Carcinomas were not
observed in the p63;p53 cohort, a result consistent with
the low percentage (1%) of carcinomas in p53mice. Thus, not
only was there a decrease in the total number of malignancies that
developed in p63 mice, the tumor spectrum was distinct from
p53-deficient mice.
Tumors Arising in p63 Mice Are Distinct from Those of p53
Compromised Mice. A frequent event in tumors that develop in
p53 mice is loss of the WT p53 allele (12). To determine
whether loss of p63 or p53 contributed to tumorigenesis, we
evaluated tumors for loss of heterozygosity (LOH) at the p63 and
p53 loci. A total of 12 lesions were analyzed for LOH at the p63
locus (3 tumors plus 2 reactive inflammatory lesions from p63
mice, and 7 p63;p53 tumors); 13 tumorswere analyzed for
LOH at the p53 locus (2 p53 tumors and 11 p63;p53
tumors). Loss of the endogenous p53 locus was observed in50%
of the tumors obtained from p53 mice (data not shown), an
observation consistent with results of previous studies. Similarly,
the WT p53 allele was lost in 50% (511) of the tumors from
p63;p53 mice. However, the p53 locus was retained in
tumors that arose in p63 mice, and loss of the endogenous
p63 locus was not observed in the tumors obtained from either
p63 or p63;p53 mice (Fig. 3A and data not shown).
RT-PCR analysis indicated that tumors from p63 mice main-
tained expression of TAp63 and Np63 isoforms (Fig. 3B). At the
protein level, p63 was most readily detected in carcinomas, an
observation consistent with p63’s well documented expression in
stratified epithelia (Fig. 7, which is published as supporting infor-
mation on the PNASweb site). Thus, loss or inactivation of theWT
p63 allele does not appear to accompany tumorigenesis in p63
mice, in striking contrast with loss of the WT p53 locus in tumors
of p53 mice.
We next examined the histopathology of tumors arising in
p63mice to compare those tumors with p53-deficient tumors.
Because lymphomas developed spontaneously in mice of each
genotype (although only five lymphomas were found in the
p63 cohort) we focused on them. Three of five lymphomas
from the p63 cohort had pathology similar to the high-grade
large cell lymphomas characteristic of p53-deficient mice (Table 3);
two lesions were of lower grade, bordering on the atypical lymphoid
hyperplasia seen in many (77%) of the p63mice (Fig. 4). This
analysis revealed that a subset of tumors in p63 mice had a
distinct pathology, in clear contrast to the unambiguous pathology
of malignant lymphomas obliterating the p53-deficient splenic or
nodal tissue.
As genomic instability is a common feature of tumors from
p53 and p53 mice (12), we used flow cytometry to assay
for genomic instability in lymphomas in p63mice.Whereas the
Table 1. Spontaneous tumor spectra in mice with compromised p63 in WT and p53-deficient backgrounds
Genotype
Tumor type
Lymphomas Sarcomas Carcinomas Other
No. of
tumors
% of
total
tumors
% of
total
cohort
No. of
tumors
% of
total
tumors
% of
total
cohort
No. of
tumors
% of
total
tumors
% of
total
cohort
No. of
tumors
% of
total
tumors
% of
total
cohort
* 24 67 32 5 14 7 7 19 10 0 0 0
p63 5 39 5 2 15 2 5 39 5 1 8 1
p53† 28 30 12 55 59 24 7 8 3 3 3 1
p63; p53 5 19 11 17 63 36 5 19 11 0 0 0
p53‡ 61 64 78 27 28 35 1 1 1 7 7 9
p63; p53‡ 14 44 50 18 56 64 0 0 0 0 0 0
*Shows only the 36 tumors that were classified (of 48 tumors found).
†The majority (80%) of p53 mice develop tumors (7,8).
‡Multiple tumors are typically found in this cohort.
Fig. 3. Tumors fromp63mice do not exhibit LOH and
retain expression of p63. (A) LOH analysis indicates
that the p53 locus is frequently lost in tumors of
p63;p53mice, whereas both p63 and p53WT
alleles are retained in tumors of p63mice. Endog-
enous (E) and targeted (T) alleles for both p63 and p53
are shown. P denotes the p53 pseudogene. (B) Tumors
were analyzed for expression of GAPDH and p63 by
RT-PCR using primers common to all p63 transcripts. In
addition, transcripts encoding TAp63 and Np63 iso-
forms were detectable in all tumors analyzed. N, non-
neoplastic; S, sarcoma; L, lymphoma; C, carcinoma; O,
other. Controls: d, water; , positive control (cDNA
library was used for GAPDH and p63; plasmids contain-
ing cDNAs for either TAp63 or Np63 isoforms were
used as positive controls for specific transcript classes);
, negative controls (plasmids containing cDNA en-
coding the opposite p63 isoform). Total RNA was pre-
pared from: sp, spleen; li, liver; t, tumor; ln, lymph
node; * indicates malignancy.
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genomes of tumors from p53 and p53 mice were often
aneuploid (Fig. 5 and data not shown), genomic instability was not
detected in malignant lymphomas from p63 mice, even in
tumors with histopathology most closely resembling that of the
high-grade tumors of p53 mice; these cells appeared diploid,
as did the nonneoplastic lesions from p63 mice. Thus, tumors
from p63 mice do not have the same degree of genomic
instability as those developing in p53mice. In contrast with the
diploid nature of p63 lymphomas, those obtained from
p63;p53 and p63;p53 mice had detectable
genomic instability (data not shown and Fig. 5), consistent with the
large number of mitotic figures observed histologically (see Fig. 4).
p63 Mice Are Not Susceptible to Chemical Carcinogenesis. We
next examined whether the well established two-stage chemical
carcinogenesis protocol (13) would enhance tumorigenesis in
p63mice. This treatment causes benign papillomas in normal
mouse skin and a proportion of these progress to squamous cell
carcinoma (SCC). In a blinded study, a cohort of 38 p63Brdm2
mice and 29 p63 sibling controls were treated with dimethyl-
benz[a]anthracenetetradecanoyl-phorbol-13-acetate and moni-
tored weekly for tumor formation, size, and number. The first
tumors in this model appeared at 10 and 12 weeks after initiation
for p63 and p63 cohorts, respectively. The percentage of
p63 mice developing tumors was approximately the same as
that of the WT cohort (P  0.19) (Fig. 6A). The average number
of tumors per mouse was not statistically different between
p63 and p63 mice over the course of the study (Fig. 6B;
P  0.46). The tumors were monitored weekly for signs of malig-
nant conversion. In contrast to p53 mice that had been
exposed to the two-stage chemical carcinogenesis protocol (14),
tumors of p63 mice did not undergo malignant conversion at
an accelerated rate relative to WT controls (Fig. 6C; P  0.07).
These data indicate that p63mice are nomore susceptible than
WT mice to chemically induced skin tumors.
Given the robust expression of p63 in the skin, we evaluated
whether p63 expression is maintained in skin tumors. Sections from
papillomas and SCCs that developed in p63 and p63mice
were immunofluorescently costained for keratin 14 and p63. Pap-
illomas from WT and p63 mice expressed p63 in a similar
nuclear pattern, and even papillomas that converted to malignant
SCC maintained robust levels of p63. Thus, loss of p63 does not
accompany tumorigenesis, even in tissues that normally express
high levels of endogenous p63.
Discussion
As p53 is themost frequentlymutated gene in human cancer (2) the
discovery of the two related proteins, p63 and p73, led to specu-
lation that these proteins would function similarly in tumor sup-
pression. However, most studies have not supported a similar
mechanism for p63 loss or inactivation, and p63 mutations have
been reported in only a few cancers (refs. 15–18 and reviewed in ref.
5). In fact, robust expression of p63 or amplification of the p63 locus
is common in many epithelial tumors (19–34). Although missense
mutations in human p63 that correlate with hot-spot mutations in
p53 have been identified, these mutations cause developmental
syndromes, rather than a predisposition to cancer (reviewed in
ref. 1).
In this study, we sought to explore the physiological role of p63
in spontaneous cancer development. While investigating the hy-
pothesis that p63 might function as a tumor suppressor, we found
that p63 heterozygosity does not accelerate tumorigenesis, even
when p53 is compromised. At the end of an extensive tumor study,
the percentage of p63 mice bearing tumors was reduced
3-fold compared with WT mice. Similarly, overall tumor inci-
dence was reduced nearly 2-fold when a single p63 heterozygous
null allele was placed in the context of a tumor-prone p53-
compromised background. So, p63 deficiency does not appear to
enhance cancer risk in the context of the whole organism, at least
when p63 heterozygosity is the initiating genetic event. Conversely,
p63 deficiency may even confer tumor protection. To take this one
step further, we investigated whether a well characterized chemical
carcinogenic insult might uncover a tumor predisposition in
Fig. 4. Histopathology of lymphomas. Tu-
mors of p53-compromised mice have
marked cytological atypia and a high mitotic
rate, similar to some lymphomas (T) from
p63 mice; other lesions were nonneo-
plastic (N) lymphoid proliferations. Lympho-
mas that developed in p63;p53
mice had a large number of mitotic figures
and apoptotic cells. (Scale bar: 100 m.)
Fig. 5. Genomic instability is not increased in lymphomas of p63-
compromised mice. Flow cytometry indicates that p53 tumors are aneu-
ploid (A), whereas both tumors (T) and nonneoplastic lesions (N) fromp63
mice are diploid (D). In contrast, tumors from p63;p53 mice are
aneuploid.
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p63mice that was not evident from evaluation of spontaneous
tumorigenesis. Although previous reports demonstrate that p53-
compromised mice are particularly prone to conversion to malig-
nant SCC in response to this two-stage chemical carcinogenesis
protocol (14), we found that p63 mice were no more suscep-
tible to this treatment than were their WT sibling controls. In
addition, robust expression of p63 is retained in both premalignant
papillomas and SCC’s of p63mice, indicating that p63 does not
function as a tumor suppressor in the skin.
The lack of spontaneous tumors in p63mice is in agreement
with the role of p63 in physiological settings. Much of our under-
standing of p63 comes from loss-of-function studies that highlight
an embryological role for p63 in orchestrating the morphogenesis
of stratified epithelia (9, 10). More recent work emphasizes p63’s
role in both cell fate determination in the embryo and maintaining
proliferative potential in mature skin (11, 35, 36). A current view of
p63 function and an emerging list of downstream targets implicate
p63 as a positive regulator of cell proliferation and cell fate,
consistent with a proposed oncogenic role in human cancers (37,
38). Thus, depending on tumor type and the initiating lesion,
compromised levels of p63 may offset the balance of cell-cycle
promoters and inhibitors, which translates to a tumor-suppressive
effect in vivo.
Recently, an independent analysis of the role of p63 in sponta-
neous tumorigenesis concluded that p63 functions as a tumor
suppressor (39). Although our results support the opposite conclu-
sion, it should be noted that distinct p63models were used in these
two studies. In any of these p63 models, it is formally possible that
partially functional p63 proteins endowed with a gain-of-function,
dominant-negative, or even hypomorphic function are expressed.
Perhaps the original differences in the phenotypes of p63-deficient
mice (40) can be explained by the distinct p63 alleles that were
generated by different laboratories. Our study used mice heterozy-
gous for p63 alleles that disrupt all p63 isoforms; therefore, we
cannot exclude the possibility that individual p63 proteins may
function in tumor suppression, or that p63 could even have a
tumor-suppressive role in certain cellular contexts or in cooperation
with particular oncogenes [e.g., E1A (41)]. Nonetheless, it should
be noted that in addition to the two models used in this current
study, we have not detected tumors in mice heterozygous for
p63Brdm3 (a third allele with a deletion of the DBD) (42), or when
p63 is ablated specifically within stratified epithelia (11). In addi-
tion, these data are in agreement with an independent study of a
defined experimental setting concluding that heterozygosity for the
p63Brdm2 allele in bothWT and p53-compromised backgrounds are
not susceptible to  irradiation-induced lymphomagenesis (43). The
lack of tumors in p63 mice is consistent with a large number
of studies of human cancers and in vivo data indicating that p63
deficiency plays a key role in modulating tumor suppressive mech-
anisms such as senescence (11), highlighting a unique role for p63
in tumorigenesis.
Experimental Procedures
Mouse Strains. p63Brdm1 and p63Brdm2 mice (9) were generated in a
mixed C57BL6J 	 129S5 genetic background (see Table 2);
p63Brdm2mice were crossed to the p53mice (7). Southern blot
analysis of BamHI-digested DNA with a 3.7-kb EcoRI probe was
used to identify p63 alleles; p53 alleles were identified by using a p53
cDNA as described (7). LOH analysis was performed by using the
same strategy used for genotyping, except that loss of the WT p63
allele was assessed by Southern blot analysis of HpaI-digested
genomic DNA.
Spontaneous Tumor Study.Acohort of 331mice [p63 (n 153),
p63;p53 (n  64), p63;p53 (n  51), p53
(n 10), p53 (n 21), and p53 (n 32)] was monitored
for tumors twice weekly for2.2 years. Tumor data from 345 mice
(WT, p53, and p53 mice) from an archival study con-
ducted in the same facility were included for reference. Mice that
were moribund, developed severe skin lesions, or had palpable
lesions were killed and subjected to necroscopy. Statistical analysis,
shown in Fig. 2A, was performed with one-way ANOVA with
Tukey’s multiple comparison test. Data in Fig. 2C were plotted by
using the Kaplan–Meier format with log-rank statistical analysis.
Chemical Carcinogenesis. Mice were shaved 2 days before initial
treatment at 8 weeks of age and as needed throughout the study.
The carcinogen dimethylbenz[a]anthracene (DMBA; Sigma) was
applied at a single subcarcinogenic dose of 50 g in 100 l of
acetone per mouse. The tumor promoter, tetradecanoyl-phorbol-
13-acetate (Sigma), was applied beginning 1 week after initiation
with DMBA, 5 g in 100 l of acetone per mouse, once a week for
25 weeks. Mice were monitored weekly for tumor formation, size,
and number.
Fig. 6. p63mice are not predisposed to chemically induced skin tumors.
p63 and p63 mice treated with dimethylbenz[a]anthracene
tetradecanoyl-phorbol-13-acetate were monitored for tumorigenesis. (A–C)
The percentage of tumor-bearing mice (A), average number of tumors per
mouse (B), and percentage of mice with carcinomas (C) indicate that p63
mice are not predisposed to skin tumors. (D) Papillomas and SCCs retain p63
expression, indicating that p63 does not function as a tumor suppressor in this
setting. Shown is expression of K14 (red) and p63 (green).
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Histology.Histological analysis ofmultiple tissueswas performedon
a total of 211 mice. Tissues were fixed in 10% buffered formalin,
dehydrated, embedded in paraffin, and sectioned at 5-m thick-
ness. Paraffin was removed, and the sections were rehydrated,
stained in hematoxylin, counterstained in eosin, and dehydrated in
an ethanol series ending in xylene. Pathology was assessed by H.V.
Immunofluorescence and Western Blotting. For Western blotting,
protein samples were prepared in Laemmli buffer, and protein
concentration was determined by Bradford protein assay (Bio-
Rad). Thirty micrograms of protein was loaded in each lane. p63
was detected by using the 4A4 anti-p63 antibody (1:800; Santa Cruz
Biotechnology), and the same blot was reprobed with actin (anti-
-actin, Sigma; 1:10,000). Tumor sections were subjected to immu-
nofluorescent analysis using the 4A4 anti-p63 antibody (1:500; a gift
fromFrankMcKeon,HarvardMedical School, Boston) and guinea
pig anti-K14 (44) antibodies. Primary antibodies were detected by
using Alexa-conjugated fluorochromes 594 goat anti-guinea pig
and 488 goat anti-mouse (Molecular Probes).
RT-PCR. Total RNAwas isolated from frozen tumors by using Trizol
reagent (Invitrogen) and a Tissue-Tek homogenizer (Brinkman).
RT-PCR was performed on 0.5 g of total RNA by using a
Superscript first-strand cDNAsynthesis kit (Invitrogen), and cDNA
was amplified by PCR using the following primers: GAPDH1,
5-AAGGTCGGTGTGAACGGATT-3; GAPDH2, 5-TGGTG-
GTGCAGGATGCATTG-3; p63N-1, 5-TTGTACCTG-
GAAAACAATG-3; p63N-2, 5-GCATCGTTTCACAAC-
CTCG-3; p63TA-1, 5-AACCCCAGCTCATTTCTC-3;
p63TA-2, 5- GGCCCGGGTAATCTGTGTTGG-3; p63DBD-1,
5-ATGGACCAGCAGATTCAGAACGG-3; and p63DBD-2,
5-GCATCGTTTCACAACCTCG-3. PCRwas performed with a
MasterCycler gradient thermocycler (Eppendorf). Reaction prod-
ucts were resolved on a 4% agarose gel.
DNA Content Analysis. Sections of 50mwere cut from each tumor,
paraffin was removed in xylene, and tissues were rehydrated in an
ethanol series. After overnight incubation in 100 gml RNaseA in
PBS, nuclei were treated with 5 mgml trypsin for 3 h and washed
in 70% ethanol. The isolated nuclei were stained with 0.5 gml
DAPI for 30 min. To determine the diploid cell population within
each tumor sample, cycling mouse embryonic fibroblasts (MEFs)
were used as an internal control. Samples were analyzed on the BD
LSRII cell analyzer (BD Biosystems) before and after addition of
paraformaldehyde-fixed MEFs, and data were analyzed by FACS
DIVA software (BD Biosystems).
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